MaxCyte Inc

NASDAQ: MXCT    
Share price (5/3/24): $3.83    
Market cap (5/3/24): $400 million
13 MaxCyte Inc Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.21
from 10-K 5 pages Material contract
12/34/56
EX-10.20
from 10-K 21 pages Material contract
12/34/56
EX-10.1
from 8-K 14 pages Severance Agreement
12/34/56
EX-10.1
from 8-K 30 pages Maxcyte, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2022 Approved by the Stockholders: June 29, 2022 Amended by the Board of Directors: April 19, 2023 Approved by the Stockholders: June 22, 2023
12/34/56
EX-10.1
from 8-K 14 pages Severance Agreement
12/34/56
EX-10.17
from 10-K 4 pages Amendment to Deed of Lease
12/34/56
EX-10.16
from 10-K 79 pages Deed of Lease
12/34/56
EX-10.15
from 10-K 11 pages ​ Severance Agreement
12/34/56
EX-10.6
from 10-Q 11 pages Maxcyte, Inc. Stock Option Grant Notice
12/34/56
EX-10.5
from 10-Q 7 pages Maxcyte, Inc. Rsu Award Grant Notice
12/34/56
EX-10.4
from 10-Q 11 pages Maxcyte, Inc. Stock Option Grant Notice
12/34/56
EX-10.3
from 10-Q 8 pages ​ Consulting Agreement ​
12/34/56
EX-10.2
from 10-Q 10 pages 1.separation. You Have Tendered and the Company Has Accepted Your Resignation From Employment With the Company Effective April 15, 2022. Your Last Day of Work With the Company and Your Employment Separation Date Will Be April 15, 2022 (The “Separation Date”). Between the Date of This Agreement and the Separation Date (“Interim Period”), You Agree to Fully Cooperate With the Company in All Matters Relating to the Transition of Your Work and Responsibilities on Behalf of the Company, Including, but Not Limited To, Any Present, Prior or Subsequent Relationships and the Orderly Transfer of Any Such Work and Institutional Knowledge to Such Other Persons as May Be Designated by the Company. Further, During the Interim Period, You Agree Not to Attend in Person or Virtually Any Company Event (Including Sales and/or Marketing Meetings), Company Sponsored Conferences and/or Seminars, Company Meetings (Including Video or Phone Teleconferences), Investor or Analysts Calls With the Company, Without Prior Written Approval of Attendance by the Company’s General Counsel. ​
12/34/56
EX-10.1
from 8-K 30 pages Maxcyte, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2022 Approved by the Stockholders: June 29, 2022
12/34/56
EX-10.17
from 10-K 4 pages Amendment to Deed of Lease
12/34/56
EX-10.16
from 10-K 79 pages Deed of Lease
12/34/56
EX-10.15
from 10-K 1 page Notice of Termination of Lease Agreement Between Are-20/22/1300 Firstfield Quince Orchard, LLC and Maxcyte, Inc. ​
12/34/56
EX-10.14
from 10-K 11 pages ​ Severance Agreement
12/34/56
EX-10.5
from 10-K 27 pages Maxcyte, Inc. 2021 Inducement Plan Adopted by the Board of Directors: December 15, 2021 ​
12/34/56
EX-10.15
from S-1/A 14 pages Severance Agreement
12/34/56